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The often fractious debate about how best to make 
publicly funded research more widely accessible 
and useable has intensiﬁ ed over recent years and 
is gradually reaching a practicable resolution. For 
exam ple, the UK’s Finch report,1 published last June 
by an independent group of academics, research 
funders, and publishers, clearly stated that the UK 
should embrace the transition to open access while 
recognising that it is important “to ensure that they 
[researchers] have eﬀ ective and high-quality channels 
through which they can publish and disseminate 
their ﬁ ndings”. 
Finch recommended that the research councils, 
together with other public sector bodies, should 
establish more eﬀ ective and ﬂ exible arrangements to 
meet the cost of publishing in open access and hybrid 
journals. As a response, Research Councils UK (RCUK) has 
reviewed and revised its policy and, from April 1, 2013, 
new guidance comes into force. The latest revision, 
released on March 6, supports both “gold” open access 
(journal mediated, with authors retaining copyright 
under a CC-BY creative commons license after paying an 
article processing charge) providing immediate access, 
and “green” open access (repository mediated, with 
authors posting the ﬁ nal accepted version of their paper 
without restriction of use) after an embargo period of 
6 months for biomedical research.2
The Lancet journals welcome and support all eﬀ orts 
to make research more widely accessible and useable in 
ways that continue to sustain our broad mission to serve 
clinical medicine and global health. We will, in accordance 
with the new RCUK policy, oﬀ er either a “gold” open 
access choice with a creative commons license after 
payment of an article processing charge of US$5000, 
or a “green” open access solution—where authors can 
deposit the ﬁ nal accepted version of their paper in any 
repository they choose 6 months after publication—
for all RCUK-funded research papers submitted after 
April 1. In addition, for the “green” open access solution 
we will also make the published paper free to access on 
our websites 6 months after publication. 
These options and a choice of three diﬀ erent crea-
tive commons licenses (CC-BY, CC BY-NC-SA, or CC BY-
NC-ND) will be open to authors of all research papers 
supported by those funders with whom we currently 
have payment agreements.
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development, and smoking remains a scourge worldwide 
in our ﬁ ght to improve health. For the ancient populations 
studied by Thompson and colleagues, infection is likely to 
provide the unifying explanation.9 A wealth of evidence 
points to a key role for inﬂ ammation in both circulatory 
and malignant processes.9 High levels of chronic infection 
and inﬂ ammation could have promoted cardiovascular 
lesion development and, although not being fatal for 
most, might have become so with the passage of time. 
These data conﬁ rm that atheroma has been a burden 
on the human circulation for centuries. Few are exempt, 
and as life expectancy lengthens owing to modern 
advances in public health and medicine, more will suﬀ er 
its consequences unless urgent measures are taken to 
prevent its legacy.
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In 2008, The Lancet published a phase 2 study of 
tesofensine as an adjunct to a hypocaloric diet in the 
treatment of obesity.1 The study was also published 
in Ugeskrift for Læger.2 In 2011, The Danish Health and 
Medicines Authority decided to inspect completed trials 
at random. This study was among those selected and 
was inspected in November of that year. Concerns were 
expressed about two of the ﬁ ve sites where the trial 
was undertaken, and were brought to the attention of 
The Lancet in 2012 by the Article’s corresponding author.
Three major points were raised by the inspection. 
First, Danish regulations require that informed consent 
is undertaken in its entirety by a medical practitioner, 
but in one site this duty had been delegated to non-
medical personnel. Second, the integrity of blinding 
was questioned in an earlier inspection in 2007, and 
rebutted by the investigators. Third, the recording and 
assessment of adverse events by the contract research 
organisation was incomplete, because their staﬀ  did not 
consider as noteworthy the recurrence of events that 
trial participants had experienced on occasions prior to 
the study. In particular, headache, migraine, stress, and 
depression were not reliably recorded in people who 
had experienced these conditions before enrolling in the 
trial. Therefore, the report concluded that “the overall 
side-eﬀ ect proﬁ le that is…published in The Lancet is not 
in accordance with the actual course of the trial”.3
The aforementioned observations raise concerns 
about this study of which readers should be aware while 
the editors await further clariﬁ cation on details from the 
Danish Health and Medicines Authority.
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Clearly, the debate on open access to publicly funded 
research is evolving and RCUK states that it “will 
undertake a comprehensive, evidence-based review of 
the eﬀ ectiveness and impact of its Open Access policy 
in 2014”. Given the rapid pace of discussions on open 
access publication, the Lancet journals will continue to 
review how we can make all publicly funded research as 
accessible and useable as possible. 
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